



# TB Times

## Mayo Clinic Center for Tuberculosis (MCCT)



### UPCOMING EVENTS

Select links for details

[Innovations in TB Series](#)  
**Culture-Negative TB**  
August 23, 2024  
Webinar

[TB Lunch and Learn](#)  
[Series](#)  
August 29, 2024  
Virtual

[TB ETN and TB PEN](#)  
[Conference](#)  
September 17-19, 2024  
Atlanta, GA  
In-person

[2024 Civil Surgeons](#)  
[Series](#)  
**The Basics and**  
**Management of LTBI**  
September 19, 2024  
Webinar

[TB Clinical Intensive](#)  
October 9-10, 2024  
Rochester, MN  
In-person

[Iowa TB Clinical](#)  
[Intensive](#)  
October 24-25, 2024  
Des Moines, IA  
In-person  
Iowa Employees Only

[Bi-State Infectious](#)  
[Disease Conference](#)  
November 8, 2024  
St. Louis, Missouri  
In-person

## TB Contact Investigation Course

This month was all about TB contact investigation! We kicked off with a course in Wauwatosa, WI, on August 6th. Special thanks to our Wisconsin Division of Public Health colleagues for collaborating with MCCT to deliver an excellent learning experience to over 50 Wisconsin healthcare workers.

Our Innovations in TB webinar series for August highlighted TB contact investigation essentials. This webinar was recorded and is now available on our website at [Self-Study Courses](#).

We are excited to offer more TB contact investigation learning opportunities soon! For more information on these courses, visit [TB Contact Investigation Courses](#) or email us at [TBcenter@mayo.edu](mailto:TBcenter@mayo.edu).

## Save the Date for Bi-State!

Join us in St. Louis, Missouri, on November 8th for the Bi-State Infectious Disease Conference. This year's theme is "How to Get to Zero" and will feature hot topics such as emerging illnesses, culture-negative TB, and updates on state healthcare-associated infections (HAI). Registration is now open. For more information, visit [Bi-State 2024](#). Don't miss this opportunity to stay informed and connect with professionals in the field.

## TB ETN / PEN Conference

We look forward to being in-person at the upcoming TB ETN/PEN Conference September 17-19<sup>th</sup> in Atlanta, GA. We hope to see you there! Please take a moment to stop by our table and join the MCCT COE breakout session where we will discuss ways to support your efforts in TB elimination.


## Lunch and Learn

Join us virtually on August 29<sup>th</sup> for our next Lunch and Learn session with Dr. Kubat, an expert in infectious diseases, as he discusses tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. [Register here](#).

## Journal Spotlight on TB

### Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis

*Mycobacterium tuberculosis* (TB) remains the leading cause of infection-related mortality worldwide. Drug resistance, need for multiple antimycobacterial agents, prolonged treatment courses, and medication-related side effects are complicating factors to TB cure. This review summarizes key information on the pharmacology and treatment principles for moxifloxacin, bedaquiline, delamanid, pretomanid, linezolid, and tedizolid in the treatment of multi-drug resistant TB.




### Investigating the efficacy of integrating video-directly observed therapy (VDOT) in the treatment of tuberculosis (TB): A statewide analysis from Florida

This study aimed to assess whether integrating Video Directly Observed Therapy (VDOT) into tuberculosis (TB) treatment in Florida was non-inferior to Directly Observed Therapy (DOT) and to examine VDOT usage trends post-Covid-19 onset. A review of TB patients treated from January 2018 to December 2018 and January 2020 to December 2021 revealed some interesting results! The study concluded that VDOT is a cost-effective, alternative to DOT, despite barriers to its broader implementation.

## New Product Release!

The Curry International Tuberculosis Center (CITC)/UCSF is pleased to announce the release of the complete [Tuberculosis Infection Control: A Practical Manual for Preventing TB, 2nd edition \(2024\)](#). The 2024 release consolidates the 2<sup>nd</sup> edition chapter updates posted online in 2022 and 2023 into one, comprehensive, downloadable online and printed book. The new format includes in-text citations and updated 2024 resources and links.



## CDC Updates

### **CDC Responds to PZA Testing Shortage**

As indicated in the July 25, 2024 letter from CDC's Division of TB Elimination (DTBE), phenotypic pyrazinamide (PZA) susceptibility testing may not be available in many laboratories because of a manufacturer issue. The list of affected lots was expanded in an August 1<sup>st</sup> communication from Becton, Dickinson and Company (BD). It is currently unknown when new BD BACTEC™ MGIT™ 960 PZA test kits might be available.

In response, CDC/DTBE is working collaboratively with the Association of Public Health Laboratories (APHL) and public health laboratory partners to provide additional capacity for *pncA* sequencing. Sequencing of *pncA* is an acceptable approach for determining PZA susceptibility as PZA resistance is primarily associated with *pncA* mutations. You can find the full notifications at [News | Center for Tuberculosis](#).

### **Limited Availability of Isoniazid 300 mg**

Recently, isoniazid 300 mg tablets were reported to FDA as limited availability by the sole manufacturer of the drug, Teva Pharmaceuticals, with estimated recovery November 2024. Please note that INH continues to be currently available from the CDC DTBE stockpile by program request. For questions about INH from the CDC stockpile, please have your TB program contact Shanica Bailey [iom5@cdc.gov](mailto:iom5@cdc.gov). Please watch for updates on FDA's drug shortage [website](#).

## **Progress toward TB elimination and TB Program Performance – National TB Indicators Project, 2016-22**

Using data to monitor TB program performance provides critical insights into program functioning and highlights both successes and areas needing improvement.

The CDC, in collaboration with various partners, developed national TB objectives, indicators, and performance targets to monitor state and city TB programs through the National TB Indicators Project (NTIP) application.

Examining TB indicator data enables state- and city-level TB programs to identify areas for program evaluation and improvement activities. These data also help CDC identify states and cities that might benefit from technical assistance. The findings in this report can be used by state and city TB programs to assess their TB control efforts and identify areas for improvement. [Read the full report here.](#)

## Newsletter Content Suggestions

We invite you to be active participants in shaping the content of our newsletter. We will do our best to provide clarity on your TB related questions and include topics and events you would like to showcase. Simply submit your ideas to [TB Times Content Suggestion](#). Each issue we will feature suggested content, making this newsletter a true reflection of your needs.

## Vision

To become a regionally, nationally, and internationally recognized Center of Excellence for tuberculosis.

## Mission

To contribute, in a meaningful way, to the control, management, and elimination of tuberculosis regionally, nationally, and globally.



## Medical Consultation

MCCT provides expert medical consultation to public health and medical professionals in our assigned region. We have colleagues with expertise in public health nursing, pharmacy, laboratory, occupational health, pediatrics, and radiology just to name a few.

Consultations can be requested using one of the following options:

- Submit at [IDCrowd Platform](#)
- Email [tbcenter@mayo.edu](mailto:tbcenter@mayo.edu)
- Call 507-284-0275

IDCrowd is the preferred platform for submitting requests used by all TB COEs. If you are using IDCrowd for the first time, choose the option to register for a new membership. Additional information on how to submit a request can be found [here](#).

## Mini Fellowships

As part of the TB COE initiatives, MCCT is providing mini-fellowship opportunities for healthcare professionals seeking to deepen their understanding of TB.

Experiences will be curated to meet individual learning needs. Some experiences that may be offered include shadowing healthcare professionals as they interact with patients, observing directly observed therapy (DOT), and participating in TB case reviews.

You can find out more information by emailing [tbcenter@mayo.edu](mailto:tbcenter@mayo.edu). To be considered for a mini fellowship, please submit an [application here](#).

## Educational Requests

MCCT is able to support a variety of TB related needs including virtual and in-person training, educational material development, and technical assistance. Please contact us to discuss ways we can support your work in treating and preventing tuberculosis.

## Contact Us



[TBcenter@mayo.edu](mailto:TBcenter@mayo.edu)



[centerfortuberculosis.mayo.edu](https://centerfortuberculosis.mayo.edu)



507-284-0275